drugset / Trial / NCT02890173

Study of CS-3150 in Patients With Essential Hypertension

NCT02890173

Phase 3 Completed 1001 enrolled Daiichi Sankyo
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.

Timeline

Start
2016-09
Primary completion
2017-07-11
Completion
2017-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject CS-3150 Unknown 2.5 mg Oral
Subject CS-3150 Unknown 5 mg Oral
Comparator Eplerenone Unknown 50 mg Oral